" class="no-js "lang="en-US"> BlueSky Immunotherapies - Medtech Alert
Monday, August 25, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
BlueSky Immunotherapies | Pharmtech Focus

BlueSky Immunotherapies

About BlueSky Immunotherapies

BlueSky Immunotherapies

BlueSky Immunotherapies GmbH (Ltd.) is a biotech company located in Vienna. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and antiviral properties. BlueSky uses these delNS-mediated properties for therapies against cancer and viral infectious diseases.

Related Story

Clinical Trials

 Equine Sarcoids - Visible Success with DelNS-based Immunotherapy Leads the Way Towards Cancer Therapy in Humans | Pharmtech Focus

Equine Sarcoids - Visible Success with DelNS-based Immunotherapy Leads the Way Towards Cancer Therapy in Humans

December 10 2021

Scientists from the Viennese biotech company BlueSky Immunotherapies GmbH (Ltd.) have used their viral vector platform delNS […]